NCLAT: Consideration of Debt Restructuring by Lenders Doesn’t Bar Member from Initiating Proceedings  ||  Delhi High Court: In Matters of Medical Evaluation, Courts Should Exercise Restraint  ||  Delhi HC: Any Person in India Has Right to Legally Import Goods from Abroad and Sell the Same  ||  Delhi HC: Waiver to Section 12(5) of Arbitration Act to be Given Once Tribunal is Constituted  ||  Supreme Court Has Asked States to Regularise Existing Court Managers  ||  SC: Union & States to Create Special POSCO Courts on Top Priority  ||  SC Upholds Authority of CERC to Award Compensation for Delays  ||  SC: Arbitral Tribunal Has Discretion to Include in Sum Awarded, Interest at Rate as it Deems Reasonab  ||  SC: Cannot Use Article 142 to Frame Guidelines on Judicial Recusal  ||  SC: Satisfaction Recorder in One EP Won’t Affect Subsequent EPs for Future Breaches    

Patent Office Rejects AcelRX's Application for Nanotab Sufentanil - (18 Sep 2015)

Indian Patent Office has refused patent application of US-based AcelRx Pharmaceuticals, Inc, for a nanotab sufentanil,which is supposed to be administered below tongue rather than swallowing a larger pill for relief. Application failed to pass the test of Section 3(d) of Patent Act.

Tags : INDIAN PATENT OFFICE  ACELRX  NANOTAB SUFENTANIL  

Share :        

Disclaimer | Copyright 2025 - All Rights Reserved